Shareholders of Tandem Diabetes would probably like to forget the past six months even happened. The stock dropped 54.1% and ...

It has been about a month since the last earnings report for Tandem Diabetes Care, Inc. (TNDM). Shares have lost about 8.9% in that time frame, underperforming the S&P 500. Will the recent negative ...

Tandem Diabetes Care, Inc. announced NEJM publication of positive results from Control-IQ+ AID technology pivotal trial in ...

Tandem Diabetes Care announced today that it launched its next-generation Control-IQ+ automated insulin delivery algorithm in ...

Tandem Diabetes Care, Inc. has a fifty-two week low of $17.64 and a fifty-two week high of $53.69. Insider Activity In other news, COO Jean-Claude Kyrillos acquired 10,538 shares of the firm’s ...

Tandem Diabetes Care (Nasdaq:TNDM) today announced positive data supporting its automated insulin delivery technology for ...

Amundi increased its holdings in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Free Report) by 42.9% in the fourth ...

Care announced publication by The New England Journal of Medicine of results from the company’s pivotal trial of ...

The use of an automated insulin delivery (AID) system reduced A1c and hyperglycemia without increasing hypoglycemia in people ...

In trading on Wednesday, shares of Tandem Diabetes Care Inc (Symbol: TNDM) entered into oversold territory, hitting an RSI reading of 29.2, after changing hands as low as $19.16 per share.

– Additional data presented at the 18th International Conference on Advanced Technologies & Treatments for Diabetes – Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and ...